| scholarly article | Q13442814 |
| P2093 | author name string | Robert H Tukey | |
| Christian P Strassburg | |||
| Peter I Mackenzie | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irinotecan | Q412197 |
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 446-50 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity | |
| P478 | volume | 62 |
| Q33861874 | A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation |
| Q39198477 | Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population. |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q28834515 | Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities |
| Q44966651 | Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease |
| Q30482258 | Drug interaction prediction using ontology-driven hypothetical assertion framework for pathway generation followed by numerical simulation |
| Q33965830 | Frequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians |
| Q44429351 | Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients |
| Q38260248 | Gene replacement therapy for genetic hepatocellular jaundice |
| Q79291107 | Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype |
| Q43195722 | Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? |
| Q28295988 | Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome) |
| Q45001560 | Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. |
| Q37249563 | Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question |
| Q46722983 | Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report |
| Q35856276 | Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer |
| Q36812605 | Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification |
| Q33728156 | Nanocrystals of a new camptothecin derivative WCN-21 enhance its solubility and efficacy |
| Q24562836 | PharmGKB summary: very important pharmacogene information for UGT1A1 |
| Q36647612 | Pharmacogenetics and irinotecan therapy |
| Q37179528 | Pharmacogenetics of Gilbert's syndrome |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
| Q37000698 | Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. |
| Q38386709 | Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases |
| Q33778773 | Reduced total serum bilirubin levels are associated with ulcerative colitis |
| Q46884250 | Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor |
| Q35620643 | The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation |
| Q40178575 | The role of chrysin and the ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice |
| Q46140095 | Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. |
| Q37165815 | Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines |
| Q37402459 | UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer |
| Q43284930 | UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal). |
| Q44825290 | Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. |
Search more.